转移性头颈癌的克隆演化与异质性:奥地利研究组分析
该研究分析386例头颈癌患者队列,对其中26例有原发灶、远处转移灶及胚系样本的患者进行257基因靶向测序及全基因组SNP分析。发现31.6%患者呈分支演化模式,与更短远处转移时间相关;2/23(8.6%)可评估患者转移灶未检出对应突变,提示可能为肺原发肿瘤。
要点
- 头颈癌转移灶与原发灶存在显著异质性,分支演化模式提示预后较差。
- 靶向测序可辅助鉴别头颈癌转移与肺原发肿瘤,避免误诊。
- 拷贝数分析可发现突变分析未检出的结构变异,补充异质性评估。
核心结论
- 靶向大规模平行测序显示头颈癌诊断时存在显著异质性,疾病进展中呈复杂演化模式。
- 拷贝数分析揭示了突变分析未检测到的额外结构改变,突变与结构变异共同贡献肿瘤异质性。
研究设计与样本
- 奥地利头颈癌登记处386例患者队列中,筛选26例具有原发灶、远处转移灶及胚系样本的患者。
- 样本经病理分析后,采用257个头颈癌常见突变基因的靶向大规模平行测序面板及全基因组SNP集进行分析。
主要发现
- 23例可评估患者中2例(8.6%)转移灶未检出对应突变,提示可能为肺原发肿瘤而非头颈癌转移。
- 31.6%的分析患者呈分支演化模式,该模式与较短远处转移时间相关(对比点状演化模式)。
- 12例可评估异时性转移患者中7例(60%)存在随时间出现的结构基因组改变。
临床怎么用
- 对头颈癌远处转移灶进行分子检测有助于鉴别第二原发肿瘤,尤其肺原发可能。
- 分支演化模式提示更短远处转移时间,或可辅助风险分层。
局限性
- 分析仅纳入26例具有原发灶、转移灶及胚系样本的患者,样本量有限。
- 研究为回顾性队列分析,结论需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumour heterogeneity and clonal evolution within a cancer patient are deemed responsible for relapse in malignancies and present challenges to the principles of targeted therapy, for which treatment modality is often decided based on the molecular pathology of the primary tumour. Nevertheless, the clonal architecture in distant relapse of head and neck cancer is fairly unknown. PATIENTS AND METHODS: For this project, we analysed a cohort of 386 patients within the Austrian Registry of head and neck cancer. We identified 26 patients with material from the primary tumour, the distant metastasis after curative first-line treatment and a germline sample for analysis of clonal evolution. After pathological analyses, these samples were analysed using a targeted massively parallel sequencing (MPS) panel of 257 genes known to be recurrently mutated in head and neck cancer plus a genome-wide SNP-set. RESULTS: Despite histological diagnosis of distant metastasis, no corresponding mutation in the supposed metastases was found in two of 23 (8.6%) evaluable patients suggesting a primary tumour of the lung instead of a distant metastasis of head and neck cancer. We observed a branched pattern of evolution in 31.6% of the analysed patients. This pattern was associated with a shorter time to distant metastasis, compared with a pattern of punctuated evolution. Structural genomic changes over time were also present in 7 of 12 (60%) evaluable patients with metachronous metastases. CONCLUSION: Targeted MPS demonstrated substantial heterogeneity at the time of diagnosis and a complex pattern of evolution during disease progression in head and neck cancer. Copy number analyses revealed additional changes that were not detected by mutational analyses. Mutational and structural changes contribute to tumour heterogeneity at diagnosis and progression.
引用
- Melchardt T, Magnes T, Hufnagl C, et al. Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group. Eur J Cancer. 2018. PMID: 29477794. doi:10.1016/j.ejca.2018.01.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。